Paraneoplastic Cerebellar Degeneration: What to Do When Corticosteroids Have Not Worked

Paraneoplastic cerebellar degeneration is a serious neurological complication arising in the context of malignancy. First-line management combines treatment of the underlying tumor with acute corticosteroid immunotherapy. When that initial approach fails to achieve adequate disease control, a structured next-line protocol is indicated.

Previous treatment — failure condition

First-line therapy — early treatment of the underlying tumor (surgery, chemotherapy, or radiotherapy) combined with corticosteroids such as intravenous methylprednisolone or equivalent oral prednisolone — aims to reduce brain inflammation and lower circulating antibody levels. When these goals are not adequately reached, escalation to the next protocol becomes necessary.

Second-line approach (overview only)

When corticosteroid monotherapy has not delivered sufficient disease control, additional immunomodulatory strategies targeting the reduction of circulating autoantibodies are considered — including immunoglobulin-based therapy and apheresis-based interventions. The full structured protocol details the selection criteria, sequencing, and clinical decision points involved in this step.

Clinical goal

The primary objective at this stage is reduction of circulating autoantibodies.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/brainsci11111414

Reduction of circulating autoantibodies can also be addressed by intravenous immunoglobulins (IVIG) or plasma exchange (PLEX).

In case of missing effect of monotherapy with corticosteroids, IVIG or PLEX should be initiated.

View source ↗